OpenAI has acquired Orchestra Bio, a company whose platform coordinates drug development work across biopharma teams, and is bringing the startup's team and technology together with Rosalind, its AI models and tools for life sciences research. OpenAI announced the acquisition on October 20, 2026. OpenAI said its goal is to help scientists make discoveries and manage the work required to turn those discoveries into treatments that reach patients sooner. Developing a new medicine takes roughly 10…
This article has been indexed from Unite.AI
Read the original article: